Occasional heartburn, upper stomach discomfort, and bloating are among the most common digestive complaints worldwide. While conventional options like antacids focus heavily on neutralizing or suppressing stomach acid, they often overlook a critical line of defense: the integrity of the mucosal lining itself.
Enter Mucosave™ FG, a clinically studied botanical ingredient. Designed to protect and soothe the delicate tissues of the upper gastrointestinal (GI) tract, Mucosave™ FG takes a structural, dual-action approach to digestive health.
What is Mucosave™ FG?
Mucosave™ FG is a standardized blend of two Mediterranean botanical extracts:
- Prickly Pear Cladode Juice Extract: Rich in specialized physical mucilaginous polysaccharides.
- Olive Leaf Extract: Standardized for biophenols (such as luteolin 7-O-glucoside).
Rather than changing the natural pH required for healthy digestion, this synergistic combination forms a physical barrier over the stomach and esophageal lining while calming underlying tissue irritation.
The Dual-Action Mechanism
The secret behind Mucosave™ FG lies in how these two plant fractions work in tandem:
The Physical Bio-Shield (Muco-adhesion)
The cladodes (the fleshy pads) of the prickly pear cactus are natural survivalists, adapted to hold water using thick polysaccharide chains. When ingested, these polysaccharides create a viscoelastic gel matrix that adheres directly to the mucosal epithelial cells of the esophagus and stomach.
Soothing & Antioxidant Defense
While the prickly pear polysaccharides form the physical shield, olive leaf polyphenols deliver targeted cellular support. Rich in olive biophenols, this fraction helps neutralize localized oxidative stress and calms irritated gastric tissue.
Emerging Prebiotic Support
Beyond supporting the stomach’s protective barrier, preliminary research suggests that Mucosave™ FG may exhibit bifidogenic prebiotic activity. In vitro studies indicate that its ability to stimulate beneficial Bifidobacteria is comparable to inulin, although additional human clinical research is needed to confirm these findings. By promoting the growth of beneficial gut bacteria, Mucosave™ FG may help support a healthy gut microbiota.
What the Clinical Research Shows
Bionap has supported Mucosave™ FG with randomized, double-blind, placebo-controlled human clinical trials. In one study published in the Journal of Clinical Medicine, 100 healthy adults experiencing upper gastrointestinal discomfort received either 400 mg/day of Mucosave™ FG or placebo for 8 weeks. Researchers evaluated digestive symptoms and quality of life using the validated Gastrointestinal Quality of Life Index (GIQLI) and Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS).
Key Findings
- Significant improvements in digestive comfort and GI-related quality of life compared with placebo.
- Overall gastrointestinal symptom improvements approached 70% over the course of the study.
- Early symptom improvements were reported during the first weeks of supplementation, with statistically significant benefits documented at 4 and 8 weeks.
- Heartburn prevalence decreased from 58% to approximately 12%.
- Throat burning declined from 41.6% to approximately 0–2%.
- Bloating decreased from 86.7% to approximately 17%.
- Nausea declined from 48.3% to approximately 8–10%.
The Bottom Line
Most conventional approaches focus on stopping stomach acid production. However, stomach acid is vital for breaking down protein, absorbing key minerals (like calcium and iron), and keeping opportunistic gut microbes in check.
Mucosave™ FG offers a refreshing, physiological alternative: it leaves essential stomach acid intact while strengthening the mucosal barrier that protects your tissues from it.